Photo taken from google images
Mar 19, 2024, 03:44
Nitin Jain: The U.S. FDA approves lisocabtagene maraleucel for adults with relapsed or refractory CLL or SLL
Nitin Jain, The Director of the Leukemia CAR-T Program at the MD Anderson Cancer Center, shared a post by Jordan Gauthier, Associate Professor at Fred Hutch Cancer Centre and University of Washington on X/Twitter, adding:
“Wonderful news for patients with CLL! Adds another treatment option for patients who have received prior BTKi and BCL2il.”
Quoting Jordan Gauthier’s post:
“The U.S. FDA approves Bristol Myers Squibb lisocabtagene maraleucel for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Kudos to all investigators and sites involved!”
Source: Nitin Jain/X and Jordan Gauthier/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19
Dec 21, 2024, 19:18
Dec 21, 2024, 18:59
Dec 21, 2024, 18:57
Dec 21, 2024, 18:54